Production and characterization of monoclonal antibodies to human sclerostin.

Hybridoma (Larchmt)

Nephrology Research, Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

Published: October 2009

We developed and characterized monoclonal antibodies directed against the amino-terminal and carboxy-terminal regions of human and mouse sclerostin (scl). Amino-terminal and carboxy-terminal scl peptides with limited homology to scl domain-containing protein-1 were synthesized using f-moc chemistry. The peptides were conjugated to keyhole limpet hemocyanin and the conjugates were used for immunization of mice. Monoclonal antibodies were obtained and characterized using bacterially expressed and insect cell-expressed recombinant scl. The amino-terminal (IgG 2aK) and carboxy-terminal (IgG 2bK) antibodies bound bioactive sclerostin that was expressed in an insect-cell expression system with dissociation constants in the nanomolar range. The antibodies are potentially useful agents that can be used for modulating sclerostin bioactivity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145175PMC
http://dx.doi.org/10.1089/hyb.2009.0036DOI Listing

Publication Analysis

Top Keywords

monoclonal antibodies
12
amino-terminal carboxy-terminal
8
scl amino-terminal
8
antibodies
5
production characterization
4
characterization monoclonal
4
antibodies human
4
sclerostin
4
human sclerostin
4
sclerostin developed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!